Jump to content

Example Queries - Selenium

From CAMIH
Revision as of 12:48, 25 November 2024 by DDeel (talk | contribs) (Created page with "== What are the indications for taking selenium? == {{#ask: Outcome topic::Selenium |?Outcome name |?Results during intervention |?Overall RoB judgment |limit=3 |headers=plain }} == Does selenium help with mucositis? == {{#ask: Outcome topic::Selenium Outcome name::Mucositis |?Outcome specification |?Results during intervention |?Results after intervention |?Overall RoB judgment |headers=plain |limit=5 }} == What helps against mucositis in cancer? (...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

What are the indications for taking selenium?

 Outcome nameResults during interventionOverall RoB judgment
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patientsEjection fractionAfter chemotherapy (8 days): significantly better cardiac ejection fraction in sodium selenite arm (mean(SD)= 63(6%)) vs. control arm (69(6%)); p <0.05high risk
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patientsToxicityAfter chemotherapy (8 days): significant less infections in sodium selenite arm (20%) compared to control arm (67%); p<0.05high risk
Büntzel et al. (2010): Limited effects of selenium in the prevention of radiation-associated toxicities - results of a randomized study in head neck cancer patientsToxicityMaximum toxicity intervention vs. control arm: dysphagia 22.7% vs. 35.3%, ageusia 22.7% vs. 47.1%, xerostomia 22.7% vs. 23.5%, and stomatitis 36.4% vs. 23.5%; no significant differences; Significant mean difference between arms only for dysphagia at week 7: mean intervention arm 1.533 vs. control 2.167 (p=0.05)some concerns
... further results

Does selenium help with mucositis?

 Outcome specificationResults during interventionResults after interventionOverall RoB judgment
Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trialOral MucositisOnset of mucositis after transplantation comparable in both selenium and placebo arm; p=0.81Overall: Cumulative incidence (grade 1-4) comparable in both selenium arm (83.8%) and placebo arm (81.1%); p=0.76; grade 3-4 mucositis significantly lower in selenium arm (10.8%) compared to placebo arm (35.1%); p=0.013 (grade 4: 2x in placebo arm, 0x in selenium arm)


Mean duration comparable (p=0.048), only duration of objective mucositis from grade 2 to 4 and back was significantly shorter in the selenium arm (3.6±1.84 days) than in the placebo arm (5.3±2.2 days); p=0.014
high risk
Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck CancerInflammation of the oral mucosa (mucositis) due to radiotherapySignificant difference for incidence of severe mucositis at week 3: selenium arm 9.8% vs. placebo arm 42.0% (p=0.017)After 7 weeks no significant differences between the selenium arm and the placebo arm for:
  • mean duration of oral mucositis (grade 1–4) (p=0.27)
  • onset of oral mucosits (p =0.31)
  • recovery (day after radiation completion (p=0.80)
  • cumulative incidence of oral mucusitis (grade 1–4) (p=0.79)


Severe oral mucositis (grade 3 or 4) was seen in 25 patients in the selenium arm and in 20 patients in the placebo arm.


Addition: Development of oral mucositis in patients with selenium levels >65 mcg/l significantly delayed from baseline (p=0.04, no further explanation given)
high risk
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neckGrade 3 or 4NAOverall: No significant differences between arms (grade 3 intervention arm 2x, placebo arm 3x, no grade 4)some concerns

What helps against mucositis in cancer? (just selenium and curcumin)

 Outcome topicResults during interventionResults after interventionOverall RoB judgment
Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trialSeleniumOnset of mucositis after transplantation comparable in both selenium and placebo arm; p=0.81Overall: Cumulative incidence (grade 1-4) comparable in both selenium arm (83.8%) and placebo arm (81.1%); p=0.76; grade 3-4 mucositis significantly lower in selenium arm (10.8%) compared to placebo arm (35.1%); p=0.013 (grade 4: 2x in placebo arm, 0x in selenium arm)


Mean duration comparable (p=0.048), only duration of objective mucositis from grade 2 to 4 and back was significantly shorter in the selenium arm (3.6±1.84 days) than in the placebo arm (5.3±2.2 days); p=0.014
high risk
Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck CancerSeleniumSignificant difference for incidence of severe mucositis at week 3: selenium arm 9.8% vs. placebo arm 42.0% (p=0.017)After 7 weeks no significant differences between the selenium arm and the placebo arm for:
  • mean duration of oral mucositis (grade 1–4) (p=0.27)
  • onset of oral mucosits (p =0.31)
  • recovery (day after radiation completion (p=0.80)
  • cumulative incidence of oral mucusitis (grade 1–4) (p=0.79)


Severe oral mucositis (grade 3 or 4) was seen in 25 patients in the selenium arm and in 20 patients in the placebo arm.


Addition: Development of oral mucositis in patients with selenium levels >65 mcg/l significantly delayed from baseline (p=0.04, no further explanation given)
high risk
Mansourian et al. (2015): The effect of "curcuma Longa" topical gel on radiation -induced oral mucositis in patients with head and neck cancerCurcuminSignificant difference between intervention vs. placebo arm in mean (SD): intervention 3.7 (2.1) vs. placebo 7.9 (2.0); p < 0.001NAsome concerns
Mansourian et al. (2015): The effect of "curcuma Longa" topical gel on radiation -induced oral mucositis in patients with head and neck cancerCurcuminMax. degree of mucositis (number (%) of patients):
  • Grade 1: Intervention arm: 15 (78.9%), Placebo arm: 3 (16.7%)
  • Grade 2: Intervention arm: 4 (21.1%), Placebo arm: 8 (44.4%)
  • Grade 3: Intervention arm: 0 (0%), Placebo arm: 7 (38.9%)
  • Grade 4: Intervention arm and Placebo arm: 0
  • Difference between arms in distribution of grades: p < 0.001
  • Time between T0 and onset of max. mucositis: no numbers given; p = 0.315


Incidence of max. mucositis (number (%)):

  • 7 days: Intervention arm: 4 (21.1%), Placebo arm: 8 (44.4%)
  • 14 days: Intervention arm: 6 (31.6%), Placebo arm: 4 (22.2%)
  • 21 days: Intervention arm: 9 (47.4%), Placebo arm: 6 (33.3%)
NAsome concerns
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neckSeleniumNAOverall: No significant differences between arms (grade 3 intervention arm 2x, placebo arm 3x, no grade 4)some concerns
... further results